Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) PT at $8.20

Gain Therapeutics, Inc. (NASDAQ:GANX) has received a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.20.

A number of equities research analysts have commented on GANX shares. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, November 25th. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Scotiabank started coverage on shares of Gain Therapeutics in a research report on Friday. They issued a “sector outperform” rating and a $12.00 target price for the company. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $65,000. Northern Trust Corp boosted its holdings in shares of Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $198,000. Jones Financial Companies Lllp boosted its holdings in shares of Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares during the last quarter. Finally, Sprott Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $30,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Price Performance

Shares of GANX opened at $1.88 on Friday. The company has a market capitalization of $49.87 million, a P/E ratio of -1.71 and a beta of 0.14. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $2.25 and a 200 day moving average of $1.96. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $4.80.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.